WeVote
Log In

Bill

Bill

S 4412

Permits pharmacists to administer certain long-acting injectable drugs.

2024-2025 Regular Session Introduced by Tony Bucco and 1 co-sponsor

New Jersey bill authorizing licensed pharmacists to administer specified long-acting injectable medications, expanding clinical pharmacy services and patient access to routine treatments.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
#pharmaceutic
0
WeVote Research Nonpartisan
Bill Summary · S 4412

Legislative bill overview

S 4412 permits licensed pharmacists in New Jersey to administer certain long-acting injectable medications to patients, expanding the scope of clinical services pharmacists can provide beyond traditional dispensing roles. The bill specifies which drug categories qualify for pharmacist administration and establishes relevant oversight and training requirements. This aligns with similar expansions in other states that have recognized pharmacists' clinical capabilities.

Why is this important

Expanding pharmacist administration authority can improve medication access and patient convenience by reducing reliance on physician appointments for routine injectable treatments—particularly beneficial for patients in underserved areas or those with limited healthcare access. However, it also shifts clinical responsibilities traditionally held by prescribers, requiring clear quality assurance mechanisms and liability frameworks. The change affects healthcare workforce dynamics, reimbursement structures, and patient safety protocols across New Jersey's healthcare system.

Potential points of contention

  • Scope of practice boundaries: Medical professionals may argue pharmacists lack sufficient clinical training for certain injectable administrations, while pharmacy advocates counter that pharmacists receive extensive pharmaceutical education and have successfully administered vaccines and other injectables in various states.
  • Patient safety and liability: Questions remain about oversight protocols, adverse event reporting, malpractice insurance requirements, and whether pharmacist-administered treatments carry different quality standards than physician-administered ones.
  • Economic and professional interests: Physician groups may perceive revenue loss from routine injection services, while pharmacies view this as essential scope expansion; reimbursement parity between pharmacist and physician administration remains undefined.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.